Metabolic and histologic effects of recombinant canine somatotropin on bone healing in dogs, using an unstable ostectomy gap model

Brent E. Wilkens From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Brent E. Wilkens in
Current site
Google Scholar
PubMed
Close
 DVM
,
Darryl L. Millis From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Darryl L. Millis in
Current site
Google Scholar
PubMed
Close
 MS, DVM
,
Gregory B. Daniel From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Gregory B. Daniel in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Linda Munson From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Linda Munson in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Kanaiyala R. Patel From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Kanaiyala R. Patel in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Frances C. Buonomo From the Departments of Small Animal Clinical Sciences (Wilkens, Millis, Daniel) and Pathology (Munson), College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37901-1071, and Protiva, a unit of Monsanto Company, St Louis, MO 63198 (Patel, Buonomo).

Search for other papers by Frances C. Buonomo in
Current site
Google Scholar
PubMed
Close
 PhD

Click on author name to view affiliation information

Abstract

Objective

To investigate the effect of recombinant canine somatotropin (STH) on the metabolic and histologic aspects of bone healing in dogs, using an unstable os-tectomy gap model.

Animals

8 mature dogs.

Procedure

A 3-mm ostectomy of the mid portion of the radius was performed in all dogs. Implants designed to release STH at a rate of 4 mg/d were placed SC in 4 dogs (treated group [STHG]), and another 4 dogs received no implants (control group ICG]). Serum concentrations of STH, insulin-like growth factor I, and osteocalcin were de-termined before surgery, and weekly for 8 weeks. Scinti-graphic evaluation of the ostectomy sites was performed before surgery, and at weeks 2, 4, 6, and 8 after surgery. Histologic evaluation of the ostectomy sites was performed at the conclusion of the study at week 8.

Results

Significant (P < 0.05) increases in serum STH, insulin-like growth factor I, and osteocalcin concentrations were observed in dogs of the STHG during the 8-week study period. Scintigraphic activity of the ostectomy sites was increased in dogs of both groups, but dogs of the STHG had significantly (P < 0.05) greater activity, compared with dogs of the CG. Coalescence of nuclear activity across the ostectomy site was observed in dogs of the STHG, whereas dogs of the CG maintained 2 distinct areas of metabolic activity. Histologically, dogs of the STHG had bridging calluses with areas of endochondral ossification and ongoing osteogenic activity, whereas dogs of the CG had nonossified fibrocartilage typical of nonunion fractures.

Conclusion

Using the ostectomy gap model, recombinant canine STH enhanced the metabolic and histologic aspects of bone healing in dogs. (Am J Vet Res 1996;57:1395–1401)

Abstract

Objective

To investigate the effect of recombinant canine somatotropin (STH) on the metabolic and histologic aspects of bone healing in dogs, using an unstable os-tectomy gap model.

Animals

8 mature dogs.

Procedure

A 3-mm ostectomy of the mid portion of the radius was performed in all dogs. Implants designed to release STH at a rate of 4 mg/d were placed SC in 4 dogs (treated group [STHG]), and another 4 dogs received no implants (control group ICG]). Serum concentrations of STH, insulin-like growth factor I, and osteocalcin were de-termined before surgery, and weekly for 8 weeks. Scinti-graphic evaluation of the ostectomy sites was performed before surgery, and at weeks 2, 4, 6, and 8 after surgery. Histologic evaluation of the ostectomy sites was performed at the conclusion of the study at week 8.

Results

Significant (P < 0.05) increases in serum STH, insulin-like growth factor I, and osteocalcin concentrations were observed in dogs of the STHG during the 8-week study period. Scintigraphic activity of the ostectomy sites was increased in dogs of both groups, but dogs of the STHG had significantly (P < 0.05) greater activity, compared with dogs of the CG. Coalescence of nuclear activity across the ostectomy site was observed in dogs of the STHG, whereas dogs of the CG maintained 2 distinct areas of metabolic activity. Histologically, dogs of the STHG had bridging calluses with areas of endochondral ossification and ongoing osteogenic activity, whereas dogs of the CG had nonossified fibrocartilage typical of nonunion fractures.

Conclusion

Using the ostectomy gap model, recombinant canine STH enhanced the metabolic and histologic aspects of bone healing in dogs. (Am J Vet Res 1996;57:1395–1401)

Advertisement